E 2 TD 4110111=-		oplication Number	09/782,804
TRANSMITTAL	Fil	ling Date	February 13, 2001
FORM (to be used for all correspondence after initial filing)		rst Named Inventor	February 13, 2001  SIRHAN, Motasim et al.  3738
		t Unit	3738 <sup>M</sup> O <sub>LOO</sub>
		caminer Name	PHAN, Hieu 020460-000940US
Total Number of Pages in This Submission	n 8 At	torney Docket Number	020460-000940US
	ENCLOSUR	ES (Check all that apply)	
Fee Transmittal Form	☐ Drawing(s)		After Allowance Communication Group
Fee Attached	Licensing-related Papers		Appeal Communication to Board Appeals and Interferences
Amendment / Reply	Petition		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application		Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address		Status Letter
Extension of Time Request	Terminal Disclaimer		Other Enclosure(s) (please identify below):
Express Abandonment Request	Request for Refund		Return Postcard; and
	CD, Number of CD(s)		2. A copy of each of 2 references.
Supplemental Information Disclosure Statement (2 pgs) w/attached International Search Report (4 pages), w/attached PTO/SB/08A (1 pg, (citing refs 1-2)			
Certified Copy of Priority Document(s)	The Commissioner is Deposit Account 20-1		authorized to charge any additional fees 430.
Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	* Note: References not included in the total number of pages above		
SIGNA	ATURE OF APP	LICANT, ATTORNEY, C	DR AGENT
Firm Townsend and To or Nena Bains	wnsend and Crew LLP Reg. No. 47,400		
Signature		6	
Date 3 · /3	. 1) 3	<i>Y</i>	

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: |

**ROSALINDA M. SANTOS** Typed or printed

Signature

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. I hereby certify that this correspondence is I deposited with the United Attorney Docket No.: 020460-000940US States Postal Service as first class mail in an envelope addressed to **Assistant Commissioner for Patents** RECEIVED Source
MAR 20 2003 S. Buyce
TECHNOLOGY CENTER R3700 5/15/23 Washington, D.C. 20231 03.13.02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SIRHAN, Motasim et al.

Application No.: 09/782,804

Filed: February 13, 2001

For: INTRAVASCULAR DELIVERY

OF METHYLPREDNISOLONE

Examiner: PHAN, Hieu

Art Unit: 3738

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT UNDER 37** 

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A is being called to the attention of the Examiner. A copy of the Search Report corresponding to PCT Application No. PCT/US02/34350 is enclosed. Copies of two U.S. Patents listed on the PCT Search Report are also enclosed. A copy of the remaining reference listed on the PCT Search Report was previously submitted with an Information Disclosure Statement directed to the above-identified application. Accordingly, a copy is not submitted herewith.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

## **CERTIFICATION**

I hereby certify that each item of information contained in this Information

Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Reg. No. 47,400

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

NB:rms

PA 3290638 v1